What is the P/E ratio of Pharmesis International 2024?
The P/E ratio cannot be calculated for Pharmesis International at the moment.
Access the world's leading financial data and tools
Subscribe for $2 
Overview
Profile
Pharmesis International stock stock price, forecast, news, chart, split, dividend and analysis Pharmesis International ariva, Pharmesis International onvista, Pharmesis International finanzen.net, Pharmesis International aktienfinder, Pharmesis International marketscreener, Pharmesis International marketwatch, Pharmesis International bloomberg, Pharmesis International handelsblatt, Pharmesis International wiwo, Pharmesis International forum
BFK.SI
SG1BH6000003
Price
Price
3.25
Today +/-
-0.02
Today %
-4.67 %
TickerBFK.SI
ISINSG1BH6000003
P
Pharmesis International stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the Pharmesis International stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the Pharmesis International stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the Pharmesis International stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze Pharmesis International's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Pharmesis International Stock Price History
| Date | Pharmesis International Price |
|---|---|
| 11/8/2024 | 3.25 undefined |
| 11/7/2024 | 3.41 undefined |
| 11/5/2024 | 3.30 undefined |
| 11/4/2024 | 3.35 undefined |
| 11/1/2024 | 3.33 undefined |
| 10/30/2024 | 3.18 undefined |
| 10/29/2024 | 3.18 undefined |
| 10/28/2024 | 3.23 undefined |
| 10/25/2024 | 3.10 undefined |
| 10/24/2024 | 3.16 undefined |
| 10/23/2024 | 3.26 undefined |
| 10/22/2024 | 3.17 undefined |
| 10/21/2024 | 2.33 undefined |
| 10/18/2024 | 3.06 undefined |
| 10/17/2024 | 2.95 undefined |
| 10/16/2024 | 3.12 undefined |
| 10/15/2024 | 2.94 undefined |
| 10/14/2024 | 2.99 undefined |
| 10/11/2024 | 2.52 undefined |
Pharmesis International Revenue, EBIT, Net Income SG1BH6000003 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Pharmesis International, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pharmesis International from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pharmesis International’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Pharmesis International. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Pharmesis International’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Pharmesis International’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pharmesis International’s growth potential.
Pharmesis International Revenue, EBIT and net profit per share
| Date | Pharmesis International Revenue | Pharmesis International EBIT | Pharmesis International Net Income |
|---|---|---|---|
| 2023 | 45.64 M undefined | -3.98 M undefined | -4.96 M undefined |
| 2022 | 50.37 M undefined | -2.24 M undefined | -3.56 M undefined |
| 2021 | 52.77 M undefined | 3.15 M undefined | 1.17 M undefined |
| 2020 | 47.11 M undefined | -3.6 M undefined | -5.83 M undefined |
| 2019 | 37.2 M undefined | -10.73 M undefined | -17.67 M undefined |
| 2018 | 64.33 M undefined | 6.88 M undefined | 1.29 M undefined |
| 2017 | 69.73 M undefined | -289,000 undefined | -2.48 M undefined |
| 2016 | 68.84 M undefined | -2.48 M undefined | -4.64 M undefined |
| 2015 | 62.4 M undefined | 3.33 M undefined | 2.45 M undefined |
| 2014 | 60.85 M undefined | -3.6 M undefined | -3.81 M undefined |
| 2013 | 64.7 M undefined | 900,000 undefined | 500,000 undefined |
| 2012 | 55.2 M undefined | -18.5 M undefined | -19.4 M undefined |
| 2011 | 61 M undefined | -18.8 M undefined | -17.1 M undefined |
| 2010 | 85.3 M undefined | -500,000 undefined | 100,000 undefined |
| 2009 | 94.8 M undefined | 4 M undefined | 1.6 M undefined |
| 2008 | 103.3 M undefined | 7.1 M undefined | 5 M undefined |
| 2007 | 95.9 M undefined | 2.5 M undefined | 800,000 undefined |
| 2006 | 104.5 M undefined | 5.9 M undefined | 4.1 M undefined |
| 2005 | 101.6 M undefined | 5.2 M undefined | 3.5 M undefined |
| 2004 | 118.5 M undefined | 32.2 M undefined | 27.7 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 118.5 M CNY | 32.2 M CNY | 27.7 M CNY |
| 2005 | 101.6 M CNY | 5.2 M CNY | 3.5 M CNY |
| 2006 | 104.5 M CNY | 5.9 M CNY | 4.1 M CNY |
| 2007 | 95.9 M CNY | 2.5 M CNY | 800,000 CNY |
| 2008 | 103.3 M CNY | 7.1 M CNY | 5 M CNY |
| 2009 | 94.8 M CNY | 4 M CNY | 1.6 M CNY |
| 2010 | 85.3 M CNY | -500,000 CNY | 100,000 CNY |
| 2011 | 61 M CNY | -18.8 M CNY | -17.1 M CNY |
| 2012 | 55.2 M CNY | -18.5 M CNY | -19.4 M CNY |
| 2013 | 64.7 M CNY | 900,000 CNY | 500,000 CNY |
| 2014 | 60.85 M CNY | -3.6 M CNY | -3.81 M CNY |
| 2015 | 62.4 M CNY | 3.33 M CNY | 2.45 M CNY |
| 2016 | 68.84 M CNY | -2.48 M CNY | -4.64 M CNY |
| 2017 | 69.73 M CNY | -289,000 CNY | -2.48 M CNY |
| 2018 | 64.33 M CNY | 6.88 M CNY | 1.29 M CNY |
| 2019 | 37.2 M CNY | -10.73 M CNY | -17.67 M CNY |
| 2020 | 47.11 M CNY | -3.6 M CNY | -5.83 M CNY |
| 2021 | 52.77 M CNY | 3.15 M CNY | 1.17 M CNY |
| 2022 | 50.37 M CNY | -2.24 M CNY | -3.56 M CNY |
| 2023 | 45.64 M CNY | -3.98 M CNY | -4.96 M CNY |
Pharmesis International Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118 | 101 | 104 | 95 | 103 | 94 | 85 | 61 | 55 | 64 | 60 | 62 | 68 | 69 | 64 | 37 | 47 | 52 | 50 | 45 |
| - | -14.41 | 2.97 | -8.65 | 8.42 | -8.74 | -9.57 | -28.24 | -9.84 | 16.36 | -6.25 | 3.33 | 9.68 | 1.47 | -7.25 | -42.19 | 27.03 | 10.64 | -3.85 | -10.00 |
| 90.68 | 88.12 | 86.54 | 85.26 | 82.52 | 84.04 | 78.82 | 63.93 | 56.36 | 60.94 | 55.00 | 53.23 | 44.12 | 44.93 | 48.44 | 51.35 | 48.94 | 48.08 | 48.00 | 44.44 |
| 107 | 89 | 90 | 81 | 85 | 79 | 67 | 39 | 31 | 39 | 33 | 33 | 30 | 31 | 31 | 19 | 23 | 25 | 24 | 20 |
| 32 | 5 | 5 | 2 | 7 | 4 | 0 | -18 | -18 | 0 | -3 | 3 | -2 | 0 | 6 | -10 | -3 | 3 | -2 | -3 |
| 27.12 | 4.95 | 4.81 | 2.11 | 6.80 | 4.26 | - | -29.51 | -32.73 | - | -5.00 | 4.84 | -2.94 | - | 9.38 | -27.03 | -6.38 | 5.77 | -4.00 | -6.67 |
| 27 | 3 | 4 | 0 | 5 | 1 | 0 | -17 | -19 | 0 | -3 | 2 | -4 | -2 | 1 | -17 | -5 | 1 | -3 | -4 |
| - | -88.89 | 33.33 | - | - | -80.00 | - | - | 11.76 | - | - | -166.67 | -300.00 | -50.00 | -150.00 | -1,800.00 | -70.59 | -120.00 | -400.00 | 33.33 |
| 16.3 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20.75 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 26.42 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Pharmesis International Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pharmesis International is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Pharmesis International stock margins SG1BH6000003 ·
The Pharmesis International margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharmesis International. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharmesis International.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Pharmesis International's sales revenue. A higher gross margin percentage indicates that the Pharmesis International retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Pharmesis International's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Pharmesis International's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pharmesis International's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pharmesis International. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pharmesis International's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Pharmesis International Margin History
| Pharmesis International Gross margin | Pharmesis International Profit margin | Pharmesis International EBIT margin | Pharmesis International Profit margin |
|---|---|---|---|
| 2023 | 45.61 % | -8.72 % | -10.86 % |
| 2022 | 47.67 % | -4.44 % | -7.07 % |
| 2021 | 47.38 % | 5.96 % | 2.22 % |
| 2020 | 50.65 % | -7.63 % | -12.37 % |
| 2019 | 53.41 % | -28.84 % | -47.5 % |
| 2018 | 48.63 % | 10.69 % | 2 % |
| 2017 | 45.12 % | -0.41 % | -3.55 % |
| 2016 | 44.45 % | -3.6 % | -6.74 % |
| 2015 | 53.42 % | 5.33 % | 3.92 % |
| 2014 | 55.36 % | -5.92 % | -6.25 % |
| 2013 | 60.28 % | 1.39 % | 0.77 % |
| 2012 | 57.79 % | -33.51 % | -35.14 % |
| 2011 | 64.1 % | -30.82 % | -28.03 % |
| 2010 | 79.13 % | -0.59 % | 0.12 % |
| 2009 | 84.07 % | 4.22 % | 1.69 % |
| 2008 | 82.58 % | 6.87 % | 4.84 % |
| 2007 | 84.46 % | 2.61 % | 0.83 % |
| 2006 | 86.6 % | 5.65 % | 3.92 % |
| 2005 | 88.09 % | 5.12 % | 3.44 % |
| 2004 | 90.8 % | 27.17 % | 23.38 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 90.8 % | 27.17 % | 23.38 % |
| 2005 | 88.09 % | 5.12 % | 3.44 % |
| 2006 | 86.6 % | 5.65 % | 3.92 % |
| 2007 | 84.46 % | 2.61 % | 0.83 % |
| 2008 | 82.58 % | 6.87 % | 4.84 % |
| 2009 | 84.07 % | 4.22 % | 1.69 % |
| 2010 | 79.13 % | -0.59 % | 0.12 % |
| 2011 | 64.1 % | -30.82 % | -28.03 % |
| 2012 | 57.79 % | -33.51 % | -35.14 % |
| 2013 | 60.28 % | 1.39 % | 0.77 % |
| 2014 | 55.36 % | -5.92 % | -6.25 % |
| 2015 | 53.42 % | 5.33 % | 3.92 % |
| 2016 | 44.45 % | -3.6 % | -6.74 % |
| 2017 | 45.12 % | -0.41 % | -3.55 % |
| 2018 | 48.63 % | 10.69 % | 2 % |
| 2019 | 53.41 % | -28.84 % | -47.5 % |
| 2020 | 50.65 % | -7.63 % | -12.37 % |
| 2021 | 47.38 % | 5.96 % | 2.22 % |
| 2022 | 47.67 % | -4.44 % | -7.07 % |
| 2023 | 45.61 % | -8.72 % | -10.86 % |
Pharmesis International Stock Sales Revenue, EBIT, Earnings per Share SG1BH6000003 ·
The Pharmesis International earnings per share therefore indicates how much revenue Pharmesis International has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Pharmesis International earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Pharmesis International's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Pharmesis International’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharmesis International's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Pharmesis International Revenue, EBIT and net profit per share
| Date | Pharmesis International Sales per Share | Pharmesis International EBIT per share | Pharmesis International Earnings per Share |
|---|---|---|---|
| 2023 | 1.73 undefined | -0.15 undefined | -0.19 undefined |
| 2022 | 2.19 undefined | -0.1 undefined | -0.15 undefined |
| 2021 | 2.29 undefined | 0.14 undefined | 0.05 undefined |
| 2020 | 2.05 undefined | -0.16 undefined | -0.25 undefined |
| 2019 | 1.62 undefined | -0.47 undefined | -0.77 undefined |
| 2018 | 2.8 undefined | 0.3 undefined | 0.06 undefined |
| 2017 | 3.03 undefined | -0.01 undefined | -0.11 undefined |
| 2016 | 2.99 undefined | -0.11 undefined | -0.2 undefined |
| 2015 | 3.01 undefined | 0.16 undefined | 0.12 undefined |
| 2014 | 3.04 undefined | -0.18 undefined | -0.19 undefined |
| 2013 | 3.24 undefined | 0.04 undefined | 0.03 undefined |
| 2012 | 2.76 undefined | -0.93 undefined | -0.97 undefined |
| 2011 | 3.05 undefined | -0.94 undefined | -0.86 undefined |
| 2010 | 4.27 undefined | -0.03 undefined | 0.01 undefined |
| 2009 | 4.74 undefined | 0.2 undefined | 0.08 undefined |
| 2008 | 5.17 undefined | 0.36 undefined | 0.25 undefined |
| 2007 | 4.8 undefined | 0.13 undefined | 0.04 undefined |
| 2006 | 5.23 undefined | 0.3 undefined | 0.21 undefined |
| 2005 | 5.08 undefined | 0.26 undefined | 0.18 undefined |
| 2004 | 7.27 undefined | 1.98 undefined | 1.7 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2004 | 7.27 CNY | 1.98 CNY | 1.7 CNY |
| 2005 | 5.08 CNY | 0.26 CNY | 0.18 CNY |
| 2006 | 5.23 CNY | 0.3 CNY | 0.21 CNY |
| 2007 | 4.8 CNY | 0.13 CNY | 0.04 CNY |
| 2008 | 5.17 CNY | 0.36 CNY | 0.25 CNY |
| 2009 | 4.74 CNY | 0.2 CNY | 0.08 CNY |
| 2010 | 4.27 CNY | -0.03 CNY | 0.01 CNY |
| 2011 | 3.05 CNY | -0.94 CNY | -0.86 CNY |
| 2012 | 2.76 CNY | -0.93 CNY | -0.97 CNY |
| 2013 | 3.24 CNY | 0.04 CNY | 0.03 CNY |
| 2014 | 3.04 CNY | -0.18 CNY | -0.19 CNY |
| 2015 | 3.01 CNY | 0.16 CNY | 0.12 CNY |
| 2016 | 2.99 CNY | -0.11 CNY | -0.2 CNY |
| 2017 | 3.03 CNY | -0.01 CNY | -0.11 CNY |
| 2018 | 2.8 CNY | 0.3 CNY | 0.06 CNY |
| 2019 | 1.62 CNY | -0.47 CNY | -0.77 CNY |
| 2020 | 2.05 CNY | -0.16 CNY | -0.25 CNY |
| 2021 | 2.29 CNY | 0.14 CNY | 0.05 CNY |
| 2022 | 2.19 CNY | -0.1 CNY | -0.15 CNY |
| 2023 | 1.73 CNY | -0.15 CNY | -0.19 CNY |
Pharmesis International business model
Pharmesis International is one of the most popular companies on Eulerpool.com.
Pharmesis International Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
Pharmesis International historical P/E ratio, EBIT multiple, and P/S ratio
Pharmesis International shares outstanding SG1BH6000003 ·
The number of shares was Pharmesis International in 2023 — This indicates how many shares 26.415 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Pharmesis International earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Pharmesis International's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Pharmesis International’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharmesis International's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 16.3 M Aktien |
| 2005 | 20 M Aktien |
| 2006 | 20 M Aktien |
| 2007 | 20 M Aktien |
| 2008 | 20 M Aktien |
| 2009 | 20 M Aktien |
| 2010 | 20 M Aktien |
| 2011 | 20 M Aktien |
| 2012 | 20 M Aktien |
| 2013 | 20 M Aktien |
| 2014 | 20 M Aktien |
| 2015 | 20.75 M Aktien |
| 2016 | 23 M Aktien |
| 2017 | 23 M Aktien |
| 2018 | 23 M Aktien |
| 2019 | 23 M Aktien |
| 2020 | 23 M Aktien |
| 2021 | 23 M Aktien |
| 2022 | 23 M Aktien |
| 2023 | 26.42 M Aktien |
Pharmesis International stock splits
In Pharmesis International's history, there have been no stock splits.
Pharmesis International shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 16.51041 % | Chung (Chia-Jung) | 5,233,800 | 0 | 4/2/2024 |
| 15.04732 % | Suntar Investment Pte. Ltd. | 4,770,000 | 0 | 4/2/2024 |
| 10.88328 % | Yu (Yi Wen) | 3,450,000 | 0 | 4/2/2024 |
| 9.46372 % | Shenzhen Sichuang Meishi Pharmaceuticals R&D Co., Ltd. | 3,000,000 | 0 | 4/2/2024 |
| 7.19621 % | Top Entrepreneur Limited | 2,281,200 | 0 | 4/2/2024 |
| 3.62776 % | Zheng (Haoyuan) | 1,150,000 | 0 | 4/2/2024 |
| 0.98868 % | Wang (Jia) | 313,410 | 0 | 4/2/2024 |
| 0.79243 % | Long (Biao) | 251,200 | 0 | 4/2/2024 |
| 0.49558 % | Zhao (Jie) | 157,100 | 0 | 4/2/2024 |
| 0.40694 % | Seet (Seow Meng Vincent) | 129,000 | 0 | 4/2/2024 |
1
2
Pharmesis International Supply Chain
| Name | Relationship | Two-week correlation | One-month correlation | Three-Month Correlation | Six-Month Correlation | One Year Correlation | Two-Year Correlation |
|---|---|---|---|---|---|---|---|
| SupplierCustomer | -0,46 |
1
Most common questions regarding Pharmesis International
What is the P/S ratio of Pharmesis International 2024?
The P/S cannot be calculated for Pharmesis International currently.
What is the Quality Investing of Pharmesis International?
The Quality Investing for Pharmesis International is 2/10.
What is the revenue of Pharmesis International 2024?
The revenue cannot currently be calculated for Pharmesis International.
How high is the profit of Pharmesis International 2024?
The profit cannot currently be calculated for Pharmesis International.
What is the business model of Pharmesis International
No history available for Pharmesis International.
What is the Pharmesis International dividend?
Pharmesis International pays a dividend of 0 CNY distributed over payouts per year.
How often does Pharmesis International pay dividends?
The dividend cannot currently be calculated for Pharmesis International or the company does not pay out a dividend.
What is the Pharmesis International ISIN?
The ISIN of Pharmesis International is SG1BH6000003.
What is the Pharmesis International ticker?
The ticker of Pharmesis International is BFK.SI.
How much dividend does Pharmesis International pay?
Over the past 12 months, Pharmesis International paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharmesis International is expected to pay a dividend of 0 CNY.
What is the dividend yield of Pharmesis International?
The current dividend yield of Pharmesis International is .
When does Pharmesis International pay dividends?
Pharmesis International pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Pharmesis International?
Pharmesis International paid dividends every year for the past 0 years.
What is the dividend of Pharmesis International?
For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.
In which sector is Pharmesis International located?
Pharmesis International is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharmesis International kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharmesis International from 11/9/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.
When did Pharmesis International pay the last dividend?
The last dividend was paid out on 11/9/2024.
What was the dividend of Pharmesis International in the year 2023?
In the year 2023, Pharmesis International distributed 0 CNY as dividends.
In which currency does Pharmesis International pay out the dividend?
The dividends of Pharmesis International are distributed in CNY.
Pharmesis International stock
Sector
Health
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website Pharmesis International
Country
People's Republic of China 🇨🇳
Currency
CNY
Initial public offering
Oct 6, 2004
GOSIN
Global Open Securities Identification Number
Cusip
Y6830T110
Market capitalization
Quality Investing
2 / 10Details
PEG
0
P/E ratio
Forward P/E ratio
0
P/S ratio
Forward P/S ratio
0
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
Pharmesis International Peer Group
Pharmesis International Eulerpool News
Pharmesis International News
Pharmesis International FIGI
| Pharmesis International Ticker | Pharmesis International FIGI |
|---|---|
| PHM:SP | BBG000CP0KW0 |
All fundamentals about Pharmesis International
Our stock analysis for Pharmesis International Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmesis International Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Pharmesis International Revenue
- Pharmesis International Net Income
- Pharmesis International P/E
- Pharmesis International P/S
- Pharmesis International EBIT
- Pharmesis International Dividend
- Pharmesis International Stocks
- Pharmesis International Market capitalization
- Pharmesis International Debt
- Pharmesis International Liabilities
- Pharmesis International Equity
- Pharmesis International AAQS
- Pharmesis International Employees
- Pharmesis International ROE
- Pharmesis International ROA
- Pharmesis International ROCE